Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry.
Helen E JoTamera J CorteIan GlaspoleChristopher GraingePeter M A HopkinsYuben MoodleyPaul N ReynoldsSally ChapmanE Haydn WaltersChristopher ZappalaHeather AllanGregory J KeirWendy A CooperAnnabelle M MaharSamantha EllisSacha MacanshNicole S GohPublished in: BMC pulmonary medicine (2019)
Neither the use of antacid therapy nor the presence of GORD symptoms affects longer term outcomes in IPF patients. This contributes to the increasing evidence that antacid therapy may not be beneficial in IPF patients and that GORD directed therapy should be considered on an individual basis to treat the symptoms of reflux.